Does the Kymera (KYMR) Form 4 show any share sales by the CFO?

The Form 4 shows only the exercise of stock options to acquire 15,000 common shares, with no reported open-market sales. The transactions are coded "M" for derivative exercise or conversion, not as sales to third parties.

Kymera CFO exercises options for 15,000 shares

Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.08 per share.

Accepted by SEC EDGAR 05/19/2026 - 07:30 AM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.08 per share. Following this transaction, he directly holds 247,588 shares of common stock and 12,653 stock options that remain outstanding and expire on August 28, 2029.

Insider Trade Summary

15,000 shares exercised/converted

Exercise 2 txns

Insider Jacobs Bruce N.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$2.08	$31K

Holdings After Transaction: Stock Option (Right to Buy) — 12,653 contracts (Direct); Common Stock — 247,588 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 27,653 to 12,653 contracts (Direct); Common Stock, 232,588 to 247,588 shares (Direct)

Footnotes (1)

F1. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Options exercised: 15,000 shares Exercise price: $2.08 per share Shares held after transaction: 247,588 shares +3 more

6 metrics

Options exercised 15,000 shares Common stock acquired via option exercise

Exercise price $2.08 per share Stock option exercise price for 15,000 shares

Shares held after transaction 247,588 shares Direct common stock holdings after exercise

Remaining options 12,653 options Stock options outstanding after exercise

Option expiration date August 28, 2029 Expiration for remaining stock options

Exercise transactions 1 non-derivative, 1 derivative Both coded M for derivative exercise/conversion

Key Terms

Stock Option (Right to Buy), Exercise or conversion of derivative security, Common Stock, fully vested and exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

fully vested and exercisable financial

"The shares underlying this stock option are fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Bruce N. Jacobs?

Kymera Therapeutics reported that CFO Bruce N. Jacobs exercised stock options for 15,000 common shares. The options carried a $2.08 exercise price, converting derivative securities into directly held stock without any reported open-market sale.

How many Kymera Therapeutics (KYMR) shares does the CFO own after this Form 4?

After the reported transactions, CFO Bruce N. Jacobs directly holds 247,588 shares of Kymera Therapeutics common stock. This figure reflects his position following the 15,000-share option exercise disclosed in the Form 4 filing.

What were the terms of the stock options exercised by the Kymera (KYMR) CFO?

The CFO exercised fully vested stock options covering 15,000 shares of Kymera common stock at an exercise price of $2.08 per share. These options were reported as a derivative security titled "Stock Option (Right to Buy)" in the filing.

How many Kymera (KYMR) stock options remain after the CFO’s exercise?

Following the transaction, 12,653 stock options remain outstanding for the CFO. These options relate to Kymera common stock and are scheduled to expire on August 28, 2029, according to the Form 4 details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobs Bruce N.

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		M		15,000	A	$2.08	247,588	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.08	05/18/2026		M			15,000	⁽¹⁾	08/28/2029	Common Stock	15,000	$0	12,653	D

Explanation of Responses:

1. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce N. Jacobs	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR